Vestibo 8mg tablets, no. 30

Dropsy of the labyrinth of the inner ear, vestibular and labyrinth disorders: dizziness, noise and pain in the ears, headache, nausea, vomiting, hearing loss; vestibular neuritis, labyrinthitis, benign positional vertigo (including after neurosurgical operations), Meniere's disease. As part of complex therapy - vertebrobasilar insufficiency, post-traumatic encephalopathy, cerebral atherosclerosis.

Inside, during meals, without chewing, with a small amount of liquid, 8-16 mg 2-4 times a day. The treatment is long-term.

Each tablet contains the active substance: betahistine dihydrochloride 8 mg.
Excipients: povidone K90, microcrystalline cellulose, lactose monohydrate, colloidal silicon dioxide, crospovidone, stearic acid, purified water (not contained in the finished product).

Hypersensitivity, pheochromocytoma, bronchial asthma, gastric ulcer and duodenal ulcer in the acute phase, pregnancy (I trimester).

With caution
Stomach ulcer or duodenal ulcer (in history), pregnancy (II-III trimester), childhood.

Trade name of the drug: Vestibo

International non-proprietary name:

Betahistine

Dosage form:

pills

Composition:

Each tablet contains the active substance: betahistine dihydrochloride 8 mg.
Excipients: povidone K90, microcrystalline cellulose, lactose monohydrate, colloidal silicon dioxide, crospovidone, stearic acid, purified water (not contained in the finished product).

Description:

Tablets 8 mg: round, flat tablets with beveled edges, white or off-white, marked 'B 8' on one side.

Pharmacotherapeutic group:

histamine drug.

Pharmacological action
Pharmacodynamics.
A synthetic analogue of histamine, has a histamine-like and vasodilating effect. It is a weak agonist of H1 receptors and a rather potent antagonist of H3 receptors. Affects the cochlear blood flow and the central vestibular apparatus. The action of betahistine includes: vasodilation in the inner ear (indirectly through NZ and H1 receptors), an inhibitory effect on the vestibular nuclei (through NZ receptors) and impulse activity of ampullary receptors. By direct agonistic action on the H1 receptors of the inner ear vessels and precapillary sphincters of the microvasculature located in the stria vascularis, as well as indirectly through the NZ receptors, it improves microcirculation and capillary permeability, normalizes endolymph pressure in the labyrinth, blood flow and blood flow basilar artery.It has a pronounced central effect, being an antagonist of NZ receptors of the nuclei of the vestibular nerve, normalizes neuronal transmission in polysynaptic neurons of the vestibular nuclei at the level of the brain stem. By indirectly acting on NS receptors, it increases the content of serotonin in the brain stem, which reduces the activity of the vestibular nuclei. It helps to eliminate disturbances from both the vestibular and cochlear apparatus: it reduces the frequency and intensity of dizziness, reduces tinnitus, and improves hearing in cases of hearing loss. Stimulates H1 receptors, therefore does not sedate or cause drowsiness.normalizes neuronal transmission in polysynaptic neurons of the vestibular nuclei at the level of the brain stem. By indirectly acting on NS receptors, it increases the content of serotonin in the brain stem, which reduces the activity of the vestibular nuclei. It helps to eliminate disturbances from both the vestibular and cochlear apparatus: it reduces the frequency and intensity of dizziness, reduces tinnitus, and improves hearing in cases of hearing loss. Stimulates H1 receptors, therefore does not sedate or cause drowsiness.normalizes neuronal transmission in polysynaptic neurons of the vestibular nuclei at the level of the brain stem. By indirectly acting on NS receptors, it increases the content of serotonin in the brain stem, which reduces the activity of the vestibular nuclei. It helps to eliminate disturbances from both the vestibular and cochlear apparatus: it reduces the frequency and intensity of dizziness, reduces tinnitus, and improves hearing in cases of hearing loss. Stimulates H1 receptors, therefore does not sedate or cause drowsiness.reduces the frequency and intensity of dizziness, reduces tinnitus, improves hearing in cases of hearing loss. Stimulates H1 receptors, therefore does not sedate or cause drowsiness.reduces the frequency and intensity of dizziness, reduces tinnitus, improves hearing in cases of hearing loss. Stimulates H1 receptors, therefore does not sedate or cause drowsiness.

Pharmacokinetics.
It is absorbed quickly, the connection with plasma proteins is low. Sscax (maximum concentration in blood plasma) - 3 hours. Almost completely excreted by the kidneys in the form of a metabolite (2-pyridylacetic acid) within 24 hours. T1 / 2 (half-life) - 3-4 hours.

Indications for use
Dropsy of the labyrinth of the inner ear, vestibular and labyrinthine disorders: dizziness, noise and pain in the ears, headache, nausea, vomiting, hearing loss; vestibular neuritis, labyrinthitis, benign positional vertigo (including after neurosurgical operations), Meniere's disease. As part of complex therapy - vertebrobasilar insufficiency, post-traumatic encephalopathy, cerebral atherosclerosis.

Contraindications
Hypersensitivity, pheochromocytoma, bronchial asthma, gastric ulcer and duodenal ulcer in the acute phase, pregnancy (I trimester).

With caution
Stomach ulcer or duodenal ulcer (in history), pregnancy (II-III trimester), childhood.

Dosage and administration
Inside, during meals, without chewing, with a small amount of liquid, 8-16 mg 2-4 times a day. The treatment is long-term.

Side effect
Dyspepsia (nausea, vomiting), skin rash, Quincke's edema.

Overdose
Symptoms: headache, facial flushing, dizziness, tachycardia, decreased blood pressure (blood pressure), bronchospasm.

Interaction with other medicinal products
Antihistamines reduce the effect of taking the drug.

Special instructions The
therapeutic effect in some cases appears only a few months after the start of treatment.

Release form
10 or 14 tablets in a blister. 3 blisters of 10 tablets or 2 blisters of 14 tablets each with instructions for use in a pack. 10, 20, 30, 60 blisters with instructions for use in a cardboard box (for hospitals).

Storage conditions
In a dry, dark place at a temperature not exceeding 25 0 C.
Keep out of the reach of children!

Shelf life is
3 years.
Do not use after the expiration date printed on the package.

Terms of dispensing from pharmacies
Prescription